Conference Coverage

VIDEO: More gonadotropin, fewer live births


 

AT 2014 ASRM

References

SAN FRANCISCO– The higher the dose of gonadotropin for ovarian stimulation, the lower the live birth rate, a retrospective study of 541,967 cycles of assisted reproductive technology showed.

The inverse correlation was less evident in older patients than in younger patients and in those who might be expected have a more normal response, Dr. Valerie L. Baker and her associates reported at the annual meeting of the American Society for Reproductive Medicine.

The findings were consistent regardless of the number of oocytes retrieved or the woman’s age, said Dr. Baker, chief of the division of reproductive endocrinology and infertility at Stanford (Calif.) University.

In a video interview, she talked about the study and why it has made her think twice about using very high doses of gonadotropins.

Dr. Baker reported financial associations with Good Start Genetics, Ovuline, Roche, the Society for Assisted Reproductive Technologies, and Teva Pharmaceuticals.

sboschert@frontlinemedcom.com

On Twitter @sherryboschert

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Questions raised over intrapartum antibiotics to prevent neonatal streptococcus B
MDedge ObGyn
AUDIO: Conjugated estrogen, bazedoxifene combo offers menopause treatment option
MDedge ObGyn
VIDEO: Causes of low libido in postmenopausal women are complex, don’t always require pharmacologic treatment
MDedge ObGyn
VIDEO: Novel and other therapies for vaginal dryness
MDedge ObGyn
Risk-reducing salpingectomy during surgery for benign indications
MDedge ObGyn
Drugs, Pregnancy, and Lactation: Herbs
MDedge ObGyn
Purified pollen extract for hot flashes did not inhibit tamoxifen’s efficacy
MDedge ObGyn
Clomiphene bests letrozole, gonadotropins for ovarian stimulation
MDedge ObGyn
Ovarian aging may be tip-off for cardiovascular risk
MDedge ObGyn
VIDEO: Ovarian function is exciting possible CV risk marker
MDedge ObGyn